
    
      Evaluate the safety and feasibility of VentriGel delivered trans-endocardially to subjects
      with left ventricular ejection fraction (LVEF) 25 to 45% secondary to MI. Secondary endpoints
      will look at efficacy variables of ESV, EDV, EF, scar mass.
    
  